BioRestorative Therapies (BRTX) announced that its Vice President of Research and Development, Francisco Silva, presented 26-52 week blinded data from the first 15 patients with chronic lumbar disc disease, cLDD, enrolled in the ongoing Phase 2 clinical trial of BRTX-100 at the Orthopaedic Research Society, ORS, annual meeting, taking place February 7-11, 2025 in Phoenix, AZ. The safety and efficacy of BRTX-100 in treating cLDD is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States. Subjects included in the trial will be randomized 2:1 to receive either BRTX-100 or placebo. No serious adverse events were reported, and there was no dose (40X106 cells) limiting toxicity at 26-52 weeks.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.